Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression

European review for medical and pharmacological sciences

Volumn 21, Issue 6, 2017, Pages 1198-1205

  Sun, L M ^a   Liu, Y C ^b   Li, W ^b   Liu, S ^b   Liu, H X ^b   Li, L W ^b   Ma, R ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAM17 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CISPLATIN; MONOCLONAL ANTIBODY; NIVOLUMAB; PLATINUM; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ADAM17 PROTEIN; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PLATINUM;

EID: 85027252280     PISSN: None     EISSN: 22840729     Source Type: Journal    
DOI: None     Document Type: Article

References (0)